logo-loader
viewVolitionRx

VolitionRx 'has a lot of shots on goal' as development of assays advances

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEAMERICAN: VNRX) discusses with Proactive's Andrew Scott the company's second quarter update and recent preliminary data from a study that showed their Nu.Q assay kits diagnosed men with aggressive prostate cancer with 94% accuracy.

Among the company’s recent wins is a sales agreement with Active Motif for an array of Research-Use-Only kits, the first of which, the Nu.Q Total assay kit is now on the market.

Additional advances include VolitionRx’s move to sign agreements to conduct two colorectal cancer research studies across Asia in collaboration with the National Taiwan University.

Quick facts: VolitionRx

Price: 4.51 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $185.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

6 days, 4 hours ago

2 min read